These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales. Bonnin RA; Bernabeu S; Emeraud C; Naas T; Girlich D; Jousset AB; Dortet L Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671303 [TBL] [Abstract][Full Text] [Related]
32. Nelson K; Rubio-Aparicio D; Sun D; Dudley M; Lomovskaya O Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32482673 [TBL] [Abstract][Full Text] [Related]
33. New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the Kaushik A; Ammerman NC; Parrish NM; Nuermberger EL Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31209013 [TBL] [Abstract][Full Text] [Related]
34. Imipenem/relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant Enterobacteriaceae from an academic medical center. Kulengowski B; Burgess DS Pathog Dis; 2019 Jun; 77(4):. PubMed ID: 31365075 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of biochemical and molecular polymorphism in extended spectrum β-lactamases of Mycobacterium tuberculosis clinical isolates. Sharma AK; Vats P Indian J Tuberc; 2019 Jan; 66(1):92-98. PubMed ID: 30797291 [TBL] [Abstract][Full Text] [Related]
36. Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen. Singh S; Gumbo T; Alffenaar JW; Boorgula GD; Shankar P; Thomas TA; Dheda K; Malinga L; Raj P; Aryal S; Srivastava S Int J Antimicrob Agents; 2023 Dec; 62(6):106968. PubMed ID: 37726063 [TBL] [Abstract][Full Text] [Related]
37. In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae. Tselepis L; Langley GW; Aboklaish AF; Widlake E; Jackson DE; Walsh TR; Schofield CJ; Brem J; Tyrrell JM Int J Antimicrob Agents; 2020 Jul; 56(1):105925. PubMed ID: 32084512 [TBL] [Abstract][Full Text] [Related]
38. Hydrolysis of clavulanate by Mycobacterium tuberculosis β-lactamase BlaC harboring a canonical SDN motif. Soroka D; Li de la Sierra-Gallay I; Dubée V; Triboulet S; van Tilbeurgh H; Compain F; Ballell L; Barros D; Mainardi JL; Hugonnet JE; Arthur M Antimicrob Agents Chemother; 2015 Sep; 59(9):5714-20. PubMed ID: 26149997 [TBL] [Abstract][Full Text] [Related]
39. Imipenem-Relebactam Susceptibility in Hernández-García M; García-Castillo M; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Cruz H; Chaves C; Duarte J; Pássaro L; Díaz-Regañón J; Cantón R Microbiol Spectr; 2022 Oct; 10(5):e0292722. PubMed ID: 36043877 [TBL] [Abstract][Full Text] [Related]
40. Comprehensive stability analysis of 13 β-lactams and β-lactamase inhibitors in Zhou J; Qian Y; Lang Y; Zhang Y; Tao X; Moya B; Sayed ARM; Landersdorfer CB; Shin E; Werkman C; Smith NM; Kim TH; Kumaraswamy M; Shin BS; Tsuji BT; Bonomo RA; Lee RE; Bulitta JB Antimicrob Agents Chemother; 2024 Mar; 68(3):e0139923. PubMed ID: 38329330 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]